{"id":"rezvilutamide-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rezvilutamide functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism is distinct from selective estrogen receptor modulators (SERMs) and provides more complete suppression of estrogen receptor activity in hormone receptor-positive breast cancer cells.","oneSentence":"Rezvilutamide is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:58.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07407283","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-03","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT07241416","phase":"PHASE3","title":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-05","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":156},{"nctId":"NCT06348264","phase":"PHASE2","title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-10-10","conditions":"Salivary Gland Neoplasm Duct","enrollment":37},{"nctId":"NCT06134271","phase":"PHASE2","title":"Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jianbin Bi","startDate":"2023-11-15","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":160},{"nctId":"NCT05983783","phase":"PHASE3","title":"Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-08-01","conditions":"Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect","enrollment":200},{"nctId":"NCT05406999","phase":"PHASE2","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-02-01","conditions":"Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer","enrollment":900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rezvilutamide Tablets","genericName":"Rezvilutamide Tablets","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rezvilutamide is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}